Teachers Retirement System of The State of Kentucky Sells 12,479 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Teachers Retirement System of The State of Kentucky cut its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) by 8.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 132,757 shares of the life sciences company’s stock after selling 12,479 shares during the period. Teachers Retirement System of The State of Kentucky owned 0.16% of Integra LifeSciences worth $8,530,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Point72 Hong Kong Ltd increased its position in shares of Integra LifeSciences by 59.6% during the first quarter. Point72 Hong Kong Ltd now owns 3,858 shares of the life sciences company’s stock valued at $248,000 after buying an additional 1,441 shares during the period. Quantbot Technologies LP increased its position in shares of Integra LifeSciences by 1,100.6% in the first quarter. Quantbot Technologies LP now owns 5,979 shares of the life sciences company’s stock worth $384,000 after purchasing an additional 5,481 shares during the last quarter. Eaton Vance Management increased its position in shares of Integra LifeSciences by 2.6% in the first quarter. Eaton Vance Management now owns 4,216,174 shares of the life sciences company’s stock worth $270,931,000 after purchasing an additional 108,831 shares during the last quarter. First Republic Investment Management Inc. increased its position in shares of Integra LifeSciences by 8.8% in the first quarter. First Republic Investment Management Inc. now owns 5,899 shares of the life sciences company’s stock worth $379,000 after purchasing an additional 479 shares during the last quarter. Finally, Guggenheim Capital LLC increased its position in shares of Integra LifeSciences by 11.0% in the first quarter. Guggenheim Capital LLC now owns 4,996 shares of the life sciences company’s stock worth $321,000 after purchasing an additional 495 shares during the last quarter. 87.33% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $45.55 on Friday. The firm has a market cap of $3.80 billion, a PE ratio of 23.12, a price-to-earnings-growth ratio of 1.57 and a beta of 1.12. Integra LifeSciences Holdings Co. has a fifty-two week low of $45.46 and a fifty-two week high of $74.98. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.76 and a current ratio of 3.85. The business has a 50 day moving average price of $52.40 and a 200-day moving average price of $57.99.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Truist Financial decreased their price objective on shares of Integra LifeSciences from $70.00 to $56.00 and set a “hold” rating on the stock in a research report on Wednesday, July 20th. Piper Sandler decreased their price objective on shares of Integra LifeSciences from $55.00 to $50.00 in a research report on Wednesday, August 24th. TheStreet lowered Integra LifeSciences from a “b-” rating to a “c+” rating in a research note on Friday, July 8th. Finally, Morgan Stanley cut their target price on Integra LifeSciences from $59.00 to $58.00 and set an “equal weight” rating for the company in a research note on Thursday, August 25th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and a consensus price target of $65.43.

Insider Activity

In related news, Director Raymond G. Murphy sold 8,000 shares of the firm’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $55.78, for a total value of $446,240.00. Following the completion of the sale, the director now owns 40,825 shares of the company’s stock, valued at $2,277,218.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Lisa Evoli sold 1,165 shares of the firm’s stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $55.81, for a total value of $65,018.65. Following the completion of the sale, the executive vice president now owns 17,997 shares of the company’s stock, valued at $1,004,412.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond G. Murphy sold 8,000 shares of the firm’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $55.78, for a total value of $446,240.00. Following the completion of the sale, the director now directly owns 40,825 shares of the company’s stock, valued at approximately $2,277,218.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 9,602 shares of company stock valued at $536,067. 4.20% of the stock is currently owned by company insiders.

Integra LifeSciences Profile

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Featured Articles

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.